LDLR and familial hyperaldosteronism: Blocking PCSK9-mediated LDLR degradation by anti-PCSK9 monoclonal antibodies has become an effective strategy for lowering LDL-C levels in patients with familial hypercholesterolemia (FH) or patients who are intolerant to statins [4].